Publications by authors named "V Fotia"
Background: The clinical value of tumor infiltrating lymphocytes (TILs) in hormone receptor-positive (HR+)/HER2- breast cancer (BC) may be unearthed by focusing on more biologically aggressive tumors. Here we deepen and describe the correlation between RS and TILs, proposing an immuno-genomic model for HR+ /HER2- BC.
Methods: We enrolled T1-T3, N0-N1 BC patients with available RS® and TILs in the context of four multicenter, prospective studies.
Article Synopsis
- The study aimed to determine if COVID-19 severity and death rates among patients with cancer improved over time during the pandemic.
- It utilized data from the OnCovid registry, which included nearly 2,800 patients with various types of cancer from 6 European countries, focusing on patient outcomes from February 2020 to February 2021.
- Results showed that the 14-day case-fatality rate significantly decreased over time, suggesting improved management and outcomes for cancer patients infected with COVID-19.
Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients.
Methods: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population.
Article Synopsis
- The study investigates the impact of COVID-19 on cancer patients, focusing on the prevalence of long-term effects (sequelae) and their influence on patient survival.
- The research involved 2,634 eligible cancer patients who had confirmed SARS-CoV-2 infections and were assessed several months after recovery to analyze their health outcomes.
- Results showed 1,557 COVID-19 survivors underwent a formal reassessment about 22 months post-cancer diagnosis, revealing insights into the effects of COVID-19 on their treatment and survival.
Background: Despite high contagiousness and rapid spread, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to heterogeneous outcomes across affected nations. Within Europe (EU), the United Kingdom (UK) is the most severely affected country, with a death toll in excess of 100,000 as of January 2021. We aimed to compare the national impact of coronavirus disease 2019 (COVID-19) on the risk of death in UK patients with cancer versus those in continental EU.
View Article and Find Full Text PDF